- cafead Aug 08, 2024 at 11:22: AM
via The pharma industry’s most valuable companies have spent the last few years playing musical chairs as they balance major wins of newer drugs with the decline of those reaching the end of their lifecycle.
Johnson & Johnson, long a mainstay at the very top of Big Pharma’s market cap list, now sits at third as sales of its immunology megablockbuster Stelara stagger in the face of incoming competition — still, the company has a rich bullpen to fall back on. Similarly, AbbVie’s powerhouse Humira is dealing with stiff biosimilar competition, but the company ranks fourth as it fills that gap with newer products.
article source
Johnson & Johnson, long a mainstay at the very top of Big Pharma’s market cap list, now sits at third as sales of its immunology megablockbuster Stelara stagger in the face of incoming competition — still, the company has a rich bullpen to fall back on. Similarly, AbbVie’s powerhouse Humira is dealing with stiff biosimilar competition, but the company ranks fourth as it fills that gap with newer products.
article source